An Evaluation Study of GPC3 Targeted Fluorescence Imaging to Guide the Surgery of Hepatocellular Carcinoma

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma. The main purposes of this study include: ① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore. ② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:

• Patients who have been diagnosed with hepatocellular carcinoma.

• Planned to receive hepatectomy.

• Liver function Child-Pugh A/B.

• GPC-3 was validated highly expressed preoperatively.

• Aged 18 to 75, and the expected lifetime is longer than 6 months.

• Approved to sign the informed consent.

Locations
Other Locations
China
The Affiliated Hospital of Southwest Medical University
RECRUITING
Luzhou
Zhuhai People's Hospital
RECRUITING
Zhuhai
Contact Information
Primary
Zeyu Zhang, Ph.D.
zhangzeyu@fingerpass.net.cn
86-18201082715
Time Frame
Start Date: 2021-09-10
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 60
Treatments
Experimental: Anti-GPC3-IRDye800CW Intraoperative Fluorescence
The patients will receive an injection of fluorophore (Anti-GPC3-IRDye800CW) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.
Related Therapeutic Areas
Sponsors
Leads: Chinese Academy of Sciences

This content was sourced from clinicaltrials.gov